News | Myriad Genetics

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

Corporate

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

Corporate

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Products

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

Corporate

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

Corporate

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

Corporate

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

Corporate

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

Corporate

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

Corporate

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

Pipeline

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

Financial

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

Corporate

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

Corporate

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

Corporate

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

Corporate